Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)

No­var­tis looks to of­fload even more of its eye prod­ucts — re­port

Fol­low­ing its re­cent trend of of­fload­ing as­sets, No­var­tis is con­tact­ing po­ten­tial buy­ers for some oph­thal­mol­o­gy as­sets, Bloomberg re­port­ed Tues­day, cit­ing peo­ple with knowl­edge of the mat­ter.

No­var­tis is work­ing with an ad­vi­sor to of­fload front-of-eye treat­ments like its dry eye drug Xi­idra, which was ap­proved in 2016 in the US but failed to get ap­proval in Eu­rope. Noth­ing is set in stone — No­var­tis could still de­cide to keep the as­sets, Bloomberg re­port­ed, and not all are in­clud­ed in a po­ten­tial sale. For ex­am­ple, Lu­cen­tis, a treat­ment for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, isn’t up for grabs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.